About Aradigm

Business Overview

Pioneering Advancements in the Pulmonary
Pharmaceutical Industry

Aradigm's senior management team and the Board of Directors have in-depth expertise and experience in the management and oversight of public health care companies and in bringing a variety of pharmaceutical and health care products to market in the U.S. and internationally. Members of the company's Scientific Advisory Board are among the world's leading experts in pulmonary medicine and inhalation drug delivery. Together, this leadership team is pioneering important advancements in the respiratory sector of the pharmaceutical industry and positioning Aradigm as a new leader in the specialty pharmaceutical market.


Executive Management


Igor Gonda, Ph.D.
President & Chief Executive Officer
Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.



Nancy Pecota
Chief Financial Officer
Ms. Pecota has more than 20 years of experience in corporate accounting and operations management. She previously served as Chief Financial Officer for NuGEN Technologies, Inc., a life sciences tools company that provides specialty reagents to pharmaceutical and diagnostics companies. Prior to that she served as a financial consultant to early- and mid-stage life sciences companies, developing fundable business models and assessing and improving internal financial preparation and reporting processes. She has served as Vice President, Finance and Administration at Signature BioScience, Inc., a venture-backed biopharmaceutical company; and as Director, Finance and Accounting for ACLARA BioSciences, Inc., a biotechnology company. Ms. Pecota holds a Bachelor of Science in Economics from San Jose State University and was among the executives named in the San Francisco Business Times "100 Most Influential Bay Area Business Women" in 2002 and 2003.



Juergen Froehlich, MD, MBA, FCPh
Chief Medical Officer
Dr. Froehlich has more than 20 years of pharmaceutical industry experience in preclinical, clinical and regulatory activities at Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers Squibb, Ipsen and Vertex Pharmaceuticals. Dr. Froehlich was closely involved in the commercialization of various drugs and biologics and alliance activities with other companies. Dr. Froehlich graduated from the Medical School at Wuerzburg University in Germany. He is a Diplomate of the American Board of Clinical Pharmacology, a Fellow of the American College of Clinical Pharmacology and a Fellow of the Faculty of Pharmaceutical Medicine. He also holds a dual executive MBA degree from the Graduate School of Business Administration in Zurich, Switzerland and from the State University of New York at Albany.



Robert A. Reed, Ph.D.
Vice President Regulatory CMC & Quality
Dr. Reed has more than 25+ years of industry experience in chemistry, manufacturing and control (CMC) guiding API development, drug product design and development, pharmaceutical product and process characterization, technology transfer and regulatory strategy and submissions, including 12 years with liposomal products. He previously served as Senior Vice President of CMC and Technical Operations at Celsion Corporation, Vice President of Pharmaceutical Operations at XenoPort, Senior Director at Pharmaceutical Research and Development at Merck and Company, and Research Scientist at The Liposome Company. While at Merck & Co., Dr. Reed directed the CMC activities of many late stage products, such as Crixivan®, Singulair® and Januvia®. At XenoPort, Dr. Reed oversaw CMC activities for their lead candidate, Horizant®. Overall, Dr. Reed has supported the commercialization of 25 drugs for global registration. Dr. Reed received his PhD from The University of North Carolina at Chapel Hill, and was awarded a NIH Post Doctoral Fellow at Princeton University. He is an American Association of Pharmaceutical Scientists Fellow and serves on the Industry Advisory Board to University of the Pacific School of Pharmacy.



David Cipolla, Ph.D.
Vice President Preclinical R&D
Dr. Cipolla holds a chemical engineering degree from MIT (S.B.) and UC Davis (M.S.) and a pharmacy degree from the University of Sydney (Ph.D.). Dr. Cipolla currently leads the preclinical research, pharmaceutical sciences and intellectual property efforts at Aradigm Corp and has served in various scientific and technical capacities at Aradigm since 1996.  Prior to joining Aradigm, Dr. Cipolla worked at Genentech, Inc. (1988-1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis.   Dr. Cipolla has contributed in a number of roles on pharmaceutical consortia (including chair of IPAC-RS), academic societies (ISAM board member) and on the editorial board of multiple scientific journals.



Janice Dahms, M.S.
Vice President Project Management
Ms. Dahms has more than 25 years of industry experience in product development and project, portfolio and alliance management. Prior to joining Aradigm, she served as Executive Director of Product Development at Intarcia Therapeutics, Senior Director of Project Management at Abgenix, and held project management and clinical operations positions at ALZA, PAREXEL and Bristol-Myers Squibb. She has experience leading projects from early through late stages of development and played a key role in the approval of 6 marketed products. Ms. Dahms built the project management organizations at Intarcia and Abgenix to address their individual needs which included oversight of outsourced work, interfaces with development partners and evaluation of potential new projects. Ms. Dahms is a graduate of Boston University and earned her M.S. in Pharmacology from the University of Chicago.





Board of Directors

Virgil D. Thompson
Chairman of the Board, Aradigm Corporation;
CEO of Spinnaker Biosciences, Inc.

Igor Gonda, Ph.D.
President & Chief Executive Officer, Aradigm Corporation

Dr. John M. Siebert
Former Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs

Frederick Hudson
Director of Supernus Pharmaceuticals, Inc.;
Former partner of KPMG, LLP

David Bell
Executive Vice President of Grifols, Inc.

Lafmin Morgan
President Global Marketing of Grifols, Inc.

Scientific Advisory Board
Aradigm's Scientific Advisory Board is a highly regarded team of scientific experts who help the Company with strategic input into the development of treatments for severe respiratory disease, and in pharmaceutical development and pulmonary drug delivery in general. The group assists the company on a variety of issues related to potential product applications, product development paths and clinical testing.

Peter R. Byron, Ph.D.
Medical College of Virginia, Virginia Commonwealth University
Expertise: Aerosol Science/Pharmaceutics

Stephen J. Farr, Ph.D.
Zogenix, Inc.
Expertise: Pulmonary Delivery/Pharmaceutics

Tunde Otulana , M.D.
Boehringer Ingelheim
Expertise: Pulmonary Medicine, Regulatory Science

Adam Wanner, Ph.D.
University of Miami
Expertise: Chronic Obstructive Pulmonary Disease (COPD)

In addition to this Scientific Advisory Board, the Company also engages other scientific and medical experts to assist on issues specific to particular indications and programs.



©2017 Aradigm Corporation. All Rights Reserved.